Formed in 2010, Synaffix BV is a Netherlands-based biotechnology company exclusively focused on continued advancement of our best-in-class antibody-drug conjugate (ADC) technology platform. As a leading innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, our vision is to become the preferred partner in the development of these complex biological therapeutics and realize our ambition – connect to cure.
We are backed by a top tier, life science-focused investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and Merck Ventures the strategic corporate venture capital fund of Merck.
Our antibody conjugation technology, GlycoConnect™, enables the design of complex biological drugs without the need for prior genetic modification and with specificity and precision similar to what is used to design modern small molecule drugs. Combined with our payload-enhancing linker technology, HydraSpace™, and the superior stability and efficacy offered by our proprietary BCN-based metal-free click chemistry, the resulting ADCs come with an expanded therapeutic index (TI) and improved manufacturability.
Our technology is mature enough to allow initiation of clinical trials within a year from the preclinical proof-of-concept. We anticipate the first-in-human studies with glycan-conjugated ADCs to be initiated by our partners in 2018.